Journals / Türk Nöroloji Dergisi / 2020 / Cilt: 26 - Sayı: 4

The Comparison of the Effects of Two Botulinum Toxin A Injection Methods, Follow the Pain and Fixed-site Fixed-dose, on Improving the Quality of Life and Headaches in Patients with Chronic Migraine: A Preliminary Randomized Clinical Trial

İki Botulinum Toksin A Enjeksiyon Yönteminin, “Ağrıyı Takip Etme” ve “Sabit Yer Sabit Doz”, Kronik Migrenli Hastalarda Yaşam Kalitesinin ve Baş Ağrısının İyileştirilmesi Üzerine Etkilerinin Karşılaştırılması: Bir Randomize Klinik Ön Çalışma

Pages
269–276
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, the results indicated a greater response to the treatment and a higher rate of drug use in the FSFD group.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Migraine headaches are one of the most common and debilitating diseases.
📊
Key Findings & Data:Botulinum toxin A (BT-A) was approved in 2010 by the Food and Drug Administration for CM as one of the treatment options.
💡
Conclusion & Impact:However, the results indicated a greater response to the treatment and a higher rate of drug use in the FSFD group.
🔬Design:Survey & Empirical Study
📍Scope:2010 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: Migraine headaches are one of the most common and debilitating diseases. Chronic migraine (CM) is a type of migraine that reduces quality of life and causes disability. Botulinum toxin A (BT-A) was approved in 2010 by the Food and Drug Administration for CM as one of the treatment options. In BT-A treatment, follow the pain (FTP), fixed-site fixed-dose (FSFD) methods, and combined injections are prevalent. This clinical trial aimed to compare the effects of two methods of BT-A injections in patients with CM to determine the method with the fewest complications, the strongest therapeutic effects, and the lowest costs in improving quality of life.Materials and Methods: In this preliminary clinical trial, 40 patients with CM were screened, and after examining the inclusion criteria, 18 patients completed the trial. After a baseline examination and experiencing a 28-day baseline period, they were randomly divided into FSFD and FTP groups. In our study, we used the Quality of Life Questionnaire, the Migraine Daily Note, and Headache Impact Test-6.Results: A total of 17 women and 1 man completed the trial. Severity and rate of headaches and quality of life scores had better changes in the following months with similar trends in both groups without a significant difference. Conclusion: The comparison of the scores showed an improvement in most patients, but there was no significant difference between the FSFD and FTP groups. However, the results indicated a greater response to the treatment and a higher rate of drug use in the FSFD group.

Özet

Amaç: Migren baş ağrıları en sık görülen ve zayıf düşüren hastalıklardan biridir. Kronik migren (KM), yaşam kalitesini düşüren ve maluliyete neden olan bir migren türüdür. Botulinum toksin A (BT-A), KM tedavisinde kullanılan tedavi seçeneklerinden biri olarak 2010 yılında Gıda ve İlaç Dairesi tarafından onaylandı. BT-A tedavisinde ağrıyı takip etme (ATE), sabit bölge sabit doz (SBSD) yöntemleri ve kombine enjeksiyonlar yaygın olarak kullanılır. Bu klinik çalışmada; en az komplikasyonu olan, en güçlü terapötik etkilere sahip ve yaşam kalitesini iyileştirmede en düşük maliyete sahip yöntemi belirlemek için KM’li hastalarda iki BT-A enjeksiyon yönteminin etkilerinin karşılaştırılması amaçlandı.Gereç ve Yöntem: Bu ön klinik çalışmada, KM’li 40 hasta tarandı ve dahil edilme kriterleri incelendikten sonra 18 hasta çalışmayı tamamladı. Temel bir incelemeden sonra ve 28 günlük bir başlangıç dönemini tecrübe ettikten sonra, hastalar rastgele olarak ATE ve SBSD gruplarına ayrıldılar. Çalışmamızda Yaşam Kalitesi Anketi, Migren Günlük Notu ve Baş Ağrısı Etki Testi-6’yı kullandık.Bulgular: Toplam 17 kadın ve 1 erkek çalışmayı tamamladı. Baş ağrısı şiddeti, sıklığı ve yaşam kalitesi skorları, her iki grupta da benzer eğilimlerle, anlamlı bir fark olmaksızın takip eden aylarda düzelme gösterdi. Sonuç: Skorların karşılaştırılması çoğu hastada bir iyileşmenin varlığını gösterdi, ancak SBSD ve ATE grupları arasında anlamlı bir fark yoktu. Bununla birlikte, SBSD grubunda tedaviye daha iyi yanıt ve daha yüksek ilaç kullanım oranı gözlendi.

🔖

Cite This Article

REZAECAIAN, M., SALEHI, H., FEKRI, M., VAKILIAN, A., AHMADINIA, H. (2022). The Comparison of the Effects of Two Botulinum Toxin A Injection Methods, Follow the Pain and Fixed-site Fixed-dose, on Improving the Quality of Life and Headaches in Patients with Chronic Migraine: A Preliminary Randomized Clinical Trial. Türk Nöroloji Dergisi, Cilt: 26 - Sayı: 4, 269–276. https://ajindex.com/articles/636672

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Ion I, Renard D, Le Floch A, et al. Monocentric prospective study into the sustained effect of incobotulinumtoxin A (XEOMIN((R))) botulinum toxin in chronic refractory migraine. Toxins (Basel) 2018;10:221
  2. Szok D, Csáti A, Vécsei L, Tajti J. Treatment of chronic migraine with onabotulinumtoxin A: mode of action, efficacy and safety. Toxins (Basel) 2015;7:2659-2673
  3. Cady RK, Schreiber CP, Porter JA, Blumenfeld AM, Farmer KU. A multi-center double-blind pilot comparison of onabotulinumtoxin A and topiramate for the prophylactic treatment of chronic migraine. Headache 2011;51:21-32
  4. Darroff RB, Mazziotta JC, Jankovic J, Pomeroy SL. Bradley’s Neurology in Clinical Practice. 7th ed. London: Elsevier, 2015
  5. Guyuron B. Migraine Surgery. 1st ed. New York: Thieme, 2018
  6. Lipton RB, Varon SF, Grosberg B, et al. Onabotulinumtoxin A improves quality of life and reduces impact of chronic migraine. Neurology 2011;77:1465-1472
  7. Yang M, Rendas-Baum R, Varon SF, Kosinski M. Validation of the Headache Impact Test (HIT-6™) across episodic and chronic migraine. Cephalalgia 2011;31:357-367
  8. Montazeri A, Goshtasebi A, Vahdaninia M, Gandek B. The short form health survey (SF-36): translation and validation study of the Iranian version. Qual Life Res 2005;14:875-882
  9. Lee MJ, Lee C, Choi H, Chung CS. Factors associated with favorable outcome in botulinum toxin A treatment for chronic migraine: a clinicbased prospective study. J Neurol Sci 2016;363:51-54
  10. Hubbard CS, Becerra L, Smith JH, et al. Brain changes in responders vs. non-responders in chronic migraine: markers of disease reversal. Front Hum Neurosci 2016;10:497
  11. Blumenfeld A, Varon S, Wilcox T, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia 2011;31:301-315
  12. Wang SJ, Wang PJ, Fuh JL, Peng KP, Ng K. Comparisons of disability, quality of life, and resource use between chronic and episodic migraineurs:a clinic-based study in Taiwan. Cephalalgia 2013;33:171-181
  13. Escher CM, Paracka L, Dressler D, Kollewe K. Botulinum toxin in the management of chronic migraine: clinical evidence and experience. Ther Adv Neurol Disord 2017;10:127-135
  14. Naprienko MV, Smekalkina LV, Surnova EA. Efficacy of different doses of botox in treatment of chronic migraine. Zh Nevrol Psikhiatr Im S S Korsakova 2017;117:44-48
  15. Negro A, Curto M, Lionetto L, Crialesi D, Martelletti P. Onabotulinumtoxin A